Compare iShares Russell 2000 ETF (IWM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs TransMedics Group Inc — how do they compare? iShares Russell 2000 ETF trades at $278.93 (market cap $77.70B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: iShares Russell 2000 ETF is far larger — about 28.4× TransMedics Group Inc's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and TransMedics Group Inc for 24 Days on average.
| IWM | TMDX | |
|---|---|---|
Market Cap | $77.70B | $2.74B |
Volume | 35,598,983 | 949,331 |
52-Week High | $305.06 | $150.42 |
52-Week Low | $229.13 | $61.99 |
Typical Hold Time | 83 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.63, showing minimal daily movement with a slight decline of 0.03%. The ETF faces bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights IWM's underperformance compared to the S&P 500 over the past decade, with concerns about its broad exposure to both profitable and unprofitable small-cap companies. The Federal Reserve's recent rate hike has added pressure on small-cap stocks, contributing to recent declines.
The outlook for IWM remains challenged by higher interest rates and broader market rotation away from small caps. While the fund provides diversified small-cap exposure, its performance has lagged behind both large-cap indices and screened small-cap alternatives. Key risks include continued Fed tightening, economic sensitivity, and the fund's inclusion of unprofitable companies. Investors seeking small-cap exposure may consider more selective alternatives with better risk-adjusted returns.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
